File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/1097-0142(19901015)66:8<1685::AID-CNCR2820660805>3.0.CO;2-W
- Scopus: eid_2-s2.0-0025013836
- PMID: 2169994
- WOS: WOS:A1990EE78300004
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil
Title | Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil |
---|---|
Authors | |
Issue Date | 1990 |
Publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741 |
Citation | Cancer, 1990, v. 66 n. 8, p. 1685-1687 How to Cite? |
Abstract | A prospective study was conducted to assess the safety and efficacy of the addition of oral verapamil to intravenous Adriamycin (doxorubicin) for the management of patients with unresectable hepatocellular carcinoma (HCC). All 28 patients studied had histologically verified disease, and cirrhosis was present in 20 of the 21 patients with adequate tissue sampling. The overall median survival was 57 days. Chemotherapy was terminated in seven patients after one course of treatment. Partial response and complete response were noted in four patients (19%) and one patient (4.8%), respectively, among the 21 patients evaluated. Side effects related to the chemotherapy were present in all patients studied. Death from fulminating sepsis occurred in three of the 13 patients with leukopenia. Symptomatic myocardial dysfunction developed in one patient. The addition of verapamil apparently did not potentiate the tumoricidal effect of systemic Adriamycin on HCC but probably did increase its complications. |
Persistent Identifier | http://hdl.handle.net/10722/172616 |
ISSN | 2023 Impact Factor: 6.1 2023 SCImago Journal Rankings: 2.887 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lai, ECS | en_HK |
dc.contributor.author | Choi, TK | en_HK |
dc.contributor.author | Cheng, CH | en_HK |
dc.contributor.author | Mok, FPT | en_HK |
dc.contributor.author | Fan, ST | en_HK |
dc.contributor.author | Tan, ESY | en_HK |
dc.contributor.author | Wong, J | en_HK |
dc.date.accessioned | 2012-10-30T06:23:45Z | - |
dc.date.available | 2012-10-30T06:23:45Z | - |
dc.date.issued | 1990 | en_HK |
dc.identifier.citation | Cancer, 1990, v. 66 n. 8, p. 1685-1687 | en_HK |
dc.identifier.issn | 0008-543X | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/172616 | - |
dc.description.abstract | A prospective study was conducted to assess the safety and efficacy of the addition of oral verapamil to intravenous Adriamycin (doxorubicin) for the management of patients with unresectable hepatocellular carcinoma (HCC). All 28 patients studied had histologically verified disease, and cirrhosis was present in 20 of the 21 patients with adequate tissue sampling. The overall median survival was 57 days. Chemotherapy was terminated in seven patients after one course of treatment. Partial response and complete response were noted in four patients (19%) and one patient (4.8%), respectively, among the 21 patients evaluated. Side effects related to the chemotherapy were present in all patients studied. Death from fulminating sepsis occurred in three of the 13 patients with leukopenia. Symptomatic myocardial dysfunction developed in one patient. The addition of verapamil apparently did not potentiate the tumoricidal effect of systemic Adriamycin on HCC but probably did increase its complications. | en_HK |
dc.language | eng | en_US |
dc.publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741 | en_HK |
dc.relation.ispartof | Cancer | en_HK |
dc.subject.mesh | Carcinoma, Hepatocellular - Drug Therapy | en_US |
dc.subject.mesh | Doxorubicin - Administration & Dosage - Therapeutic Use | en_US |
dc.subject.mesh | Drug Therapy, Combination | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Liver Neoplasms - Drug Therapy | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Prospective Studies | en_US |
dc.subject.mesh | Verapamil - Administration & Dosage - Therapeutic Use | en_US |
dc.title | Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Fan, ST: stfan@hku.hk | en_HK |
dc.identifier.email | Wong, J: jwong@hkucc.hku.hk | en_HK |
dc.identifier.authority | Fan, ST=rp00355 | en_HK |
dc.identifier.authority | Wong, J=rp00322 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1002/1097-0142(19901015)66:8<1685::AID-CNCR2820660805>3.0.CO;2-W | - |
dc.identifier.pmid | 2169994 | - |
dc.identifier.scopus | eid_2-s2.0-0025013836 | en_HK |
dc.identifier.volume | 66 | en_HK |
dc.identifier.issue | 8 | en_HK |
dc.identifier.spage | 1685 | en_HK |
dc.identifier.epage | 1687 | en_HK |
dc.identifier.isi | WOS:A1990EE78300004 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Lai, ECS=36932159600 | en_HK |
dc.identifier.scopusauthorid | Choi, TK=7202770029 | en_HK |
dc.identifier.scopusauthorid | Cheng, CH=24802108600 | en_HK |
dc.identifier.scopusauthorid | Mok, FPT=6603786245 | en_HK |
dc.identifier.scopusauthorid | Fan, ST=7402678224 | en_HK |
dc.identifier.scopusauthorid | Tan, ESY=7402263983 | en_HK |
dc.identifier.scopusauthorid | Wong, J=8049324500 | en_HK |
dc.identifier.issnl | 0008-543X | - |